Lilly Scraps Insulin Peglispro Amid Too Much Uncertainty
This article was originally published in Scrip
Executive Summary
Investors greeted Eli Lilly & Co.'s news with open arms the company was dumping its late-stage investigational types 1 and 2 diabetes treatment basal insulin peglispro (BIL) after deciding there was too much uncertainty about the product's future after issues arose concerning changes in liver fat in its Phase III IMAGINE trials.